Monte Rosa Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GLUE Nasdaq 2836 www.monterosatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Insider Ups Holding During Year - Apr 22nd, 2025 5:35 pm
Mixed data results for two Monte Rosa molecular glue degraders - Mar 21st, 2025 1:33 pm
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates - Mar 20th, 2025 2:35 pm
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs - Mar 20th, 2025 11:00 am
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 - Mar 11th, 2025 11:00 am
3 Top Cancer Biotechs to Keep An Eye On in 2025 - Mar 7th, 2025 1:22 pm
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Feb 24th, 2025 12:00 pm
Monte Rosa Therapeutics (NASDAQ:GLUE) Is In A Good Position To Deliver On Growth Plans - Jan 31st, 2025 4:33 pm
Monte Rosa Therapeutics provide corporate update, key milestones 2025 - Jan 11th, 2025 12:27 pm
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 - Jan 10th, 2025 12:00 pm
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Jan 6th, 2025 12:00 pm
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - Dec 13th, 2024 12:00 pm
Monte Rosa Closes Global License Agreement With Novartis - Dec 11th, 2024 12:45 pm
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer - Dec 11th, 2024 12:00 pm
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - Dec 11th, 2024 12:00 pm
Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study - Dec 6th, 2024 12:11 pm
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors - Dec 5th, 2024 12:00 pm
Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High? - Dec 2nd, 2024 10:44 pm
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference - Nov 26th, 2024 12:00 pm
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet - Nov 15th, 2024 2:55 pm